Instruction for use: Tavegyl

Dosage form: Solution for intravenous and intramuscular injection; Tablets

Active substance: Clemastinum

ATX

R06AA04 Clemastine

Pharmacological group:

Antiallergic agent - H1-histamine receptor blocker [H1-antihistamines]

The nosological classification (ICD-10)

T78.2 Anaphylactic shock, unspecified: Anaphylactic shock; Anaphylactoid reaction; Anaphylactoid shock; Anaphylactic shock; Anaphylactic reactions; Anaphylactic shock to drugs

T78.3 Angioedema: Edema Quincke; Laryngeal exacerbation with angioneurotic edema; Recurrent angioedema; Allergic edema; Recurrent swelling of Quincy

T78.4 Unspecified Allergy: Allergic reactions to insulin; Allergic reactions to insect stings; Allergic reactions similar to systemic lupus erythematosus; Allergic diseases; Allergic diseases of mucous membranes; Allergic diseases and conditions resulting from increased release of histamine; Allergic diseases of mucous membranes; Allergic symptoms; Allergic symptoms in the mucous membranes; Allergic reactions; Allergic reactions caused by insect bites; Allergic reactions; Allergic conditions; Allergic laryngeal edema; allergopathy; allergic conditions; Allergy; House dust allergy; Anaphylaxis; Cutaneous reactions to medications; Skin reaction to insect stings; Cosmetic allergy; Drug allergy; Acute allergic reaction; Laryngeal edema allergic genesis and background radiation; Food and drug allergy

T80.3 Reaction to AB0 incompatibility: Incorporation of incompatible blood; Transfusion of incompatible blood; Allergic reaction with blood transfusion; Incompatibility by ABO

T88.7 Pathological reaction to drug and medicines, unspecified: Allergic drug reactions; Allergic reactions to drugs; Allergic reactions to drugs; Allergic reactions to medication; Allergic reactions to taking drugs; Allergic reactions to reception of radiocontrast agents; Allergic reactions due to medication; Anaphylactic reactions to medications; Anaphylactic reactions to taking drugs; Hepatotoxic effect of drugs; Idiosyncrasy to drugs; Drug addiction; Drug-induced leukopenia; Drug-induced liver damage; Medicinal damage of the lungs; Undesirable effects of drugs; Acute allergic reaction to drugs; Idiosyncrasy toxic

Y57.5 Radiopaque Environments

Y57.9 Adverse reactions in the therapeutic use of drugs and medications, unspecified: Allergic drug reactions; Allergic reactions to medication; Allergic reactions to taking drugs; Allergic reactions to reception of radiocontrast agents; Allergic reactions due to medication; Anaphylactic reactions to medications; Anaphylactic reactions to taking drugs; Hepatotoxic effect of drugs; Idiosyncrasy to drugs; Idiosyncrasy toxic; Drug addiction; Drug-induced leukopenia; Drug-induced liver damage; Medicinal damage of the lungs; Acute allergic reaction to drugs; Toxic reactions to medicinal substances; Allergy medication; Hepatotoxic substances; Diarrhea medication; Drug fever; Medicinal intolerance; Undesirable effects of drugs

Composition

Solution for intravenous and intramuscular injection 1 amp. (2 ml)

active substance: Clemastine hydrofumarate 2.68 mg

(Equivalent to 2 mg of clemastine)

Auxiliary substances: sorbitol - 90 mg; Ethanol 140 mg; Propylene glycol 600 mg; Sodium citrate dihydrate - up to pH 6.3; Water for injection - up to 2 ml

Pharmachologic effect

Mode of action - antiallergic, antipruritic, H1-antihistamine.

Dosing and Administration

IV or IM.

Adults: 2 mg (2 ml), i.e. The contents are 1 amp. 2 times a day (morning and evening).

With the preventive purpose, the drug is injected intravenously slowly (for 2-3 min or more) at a dose of 2 mg immediately before the possible occurrence of an anaphylactic reaction or reaction in response to the use of histamine.

The drug solution can be further diluted with isotonic sodium chloride solution or 5% glucose solution in a ratio of 1: 5.

Children: IM, 0.025 mg / kg / day, divided into 2 injections.

Release form

Solution for intravenous and intramuscular injection, 1 mg / ml. 2 ml of solution into ampoules of glass type 1 (Hept. F.). At 5 amp. In a plastic pallet. 1 plastic pallet is placed in a cardboard box.

Manufacturer

Nycomed Austrian GmbH, St. Peter-Straße 25, 4020 Linz, Austria.

The owner of the registration certificate: Novartis Consumer Helms SA. Rue de Letraz, 1260 Nyon, Switzerland.

Conditions of supply of pharmacies

On prescription.

Storage conditions of the drug Tavegyl

At a temperature of 15-30 ° C.

Keep out of the reach of children.

Shelf life of the drug Tavegyl

5 years.

Do not use after the expiry date printed on the package.